Market News Archives

Telehealth After the Sugar High: Why Amwell Thinks Its Platform Days Are Just Getting Started -( $AMWL $DOCS $HIMS $TALK $TDOC )

by John F. Heerdink, Jr. May 5, 2026 597Views 0Likes

Amwell’s (NYSE: AMWL) latest story is a quiet telehealth turnaround: a company that spent the last cycle building infrastructure now talking more about operating leverage, sticky SaaS, and a disciplined path to growth – all while the rest of digital health is…

May 5, 2026 – AI Bulls Run the Show: S&P 500 and Nasdaq Write New Records While Oil Takes a Timeout -( $AAPL $AMD $AMWL $FMC $GME $INTC $INTG $MCD $NOK $SOAR Rise!)

by John F. Heerdink, Jr. May 5, 2026 7470Views 0Likes

US equities extended their record-setting run on Tuesday as mega-cap tech and AI beneficiaries pulled the tape higher again, even as oil backed off recent spikes and macro data painted a picture of solid but not spectacular growth heading into a heavy…

Pentagon Press Briefing Takes Surreal Turn With Question About Aquatic Weaponry

by John F. Heerdink, Jr. May 5, 2026 315Views 0Likes

Defense Secretary Pete Hegseth faced an unexpected challenge at a Pentagon press briefing Tuesday: dismissing claims that Iran possesses "kamikaze dolphins" capable of suicide attacks in the Strait of Hormuz. The question, which emerged from Wall Street Journal reporting on Iranian officials…

Apple, Intel, Nvidia: The Love Triangle Moving AI Chip Stocks Into a New Orbit -( $AAPL $INTC $NVDA $SSNLF $TSM )

by John F. Heerdink, Jr. May 5, 2026 602Views 0Likes

Intel’s latest rally is more than just another chip stock pop; it’s the market’s way of voting “yes” on a reshuffled AI and manufacturing order in which Intel (INTC), Apple (AAPL), and Nvidia (NVDA) are quietly rehearsing for a new ensemble performance.…

The Robotics Boom: Efficiency Up, Humans Reconsidered

by John F. Heerdink, Jr. May 5, 2026 477Views 0Likes

The factory floor used to hum with human rhythm—coffee breaks, chatter, the occasional misplaced wrench. Today, it hums differently. Precision has replaced improvisation, algorithms have replaced instinct, and the newest employee doesn’t require healthcare or sleep. Welcome to the robotics economy, where…

Amwell Positions for Profitability Push as Telehealth Sector Eyes Explosive Growth -( $AMWL $TDOC )

by John F. Heerdink, Jr. May 4, 2026 472Views 0Likes

Amwell (AMWL, $6.42) is preparing to unveil its first quarter 2026 operating results on May 5, marking a critical checkpoint in the Boston-based telehealth platform's journey toward operational cash flow breakeven. Analysts anticipate revenue of approximately $51.5 million for the quarter, with…

May 4, 2026 – Red Day, Not Doomsday: Markets Slip as AI Hype Meets Higher‑for‑Longer Reality -( $AMWL $EBAY $INTG $NVDA $PLTR $SER $TSLA Rise!)

by John F. Heerdink, Jr. May 4, 2026 7360Views 0Likes

US stocks opened the first full week of May on the back foot, with all three major indices closing lower Monday as investors digested big AI‑software earnings against a still higher‑for‑longer macro and rates backdrop. The tone was risk‑off rather than panicked:…

GameStop’s $56 Billion eBay Play: Ryan Cohen Bets Big, Talks Small -( $AMZN $GME $EBAY )

by John F. Heerdink, Jr. May 4, 2026 530Views 0Likes

GameStop (GME) is trying on a new costume: from mall-based meme stock to would‑be e‑commerce juggernaut. The company has lobbed a roughly $55–56 billion cash‑and‑stock offer for eBay (EBAY), proposing $125 per share, a premium to where eBay traded before the news hit.…

Griffin, Gold Tip, and AllCornhole: Escalade Levels Up -( $ESCA )

by John F. Heerdink, Jr. May 4, 2026 610Views 0Likes

Evansville, Indiana's Escalade, Incorporated (NASDAQ: ESCA) is quietly assembling the kind of small‑cap playbook Wall Street tends to notice late: a focused portfolio of enthusiast brands, earnings power trending up, a CEO with real skin in the game, and a steady drip…

From Molecules to Millions: How Eupraxia, Eli Lilly and Merck Navigate the FDA Maze -( $EPRX $LLY $MRK )

by John F. Heerdink, Jr. May 4, 2026 467Views 0Likes

The modern FDA approval maze is becoming less a straight corridor and more a high-speed roundabout—and investors riding with Eupraxia Pharmaceuticals (EPRX), Eli Lilly (LLY) and Merck (MRK) may find that’s exactly where outsized opportunity lives. From Wall Poster to Wall Street…

Market News

Your Guide To Staying Informed In The Markets